MassBio said young Massachusetts biotech companies are missing out on a venture funding rebound, with seed and Series A dynamics moving in opposite directions. The report indicates that funding is tightening for the earliest stages that typically carry the highest scientific risk, even as some indicators of public-market interest and exits improve. The message aligns with broader concerns among stakeholders that the biotech “flywheel” depends on consistent investment before projects reach de-risking milestones. If early rounds shrink, follow-on pipeline generation may slow in subsequent years. For operators and founders in the region, the update highlights where capital allocation is concentrating and where strategic partnerships or platform validation efforts may become increasingly important. The report also adds a governance lens: what looks like sector recovery on aggregate may still mask uneven support across company cohorts.